Evidence map›Paper›PMID 37390496›Full record

ArticleACS applied materials & interfaces2023

Exploring the Origin of the Thermal Sensitivity of Near-Infrared-II Emitting Rare Earth Nanoparticles.

Khouloud Hamraoui, Vivian Andrea Torres-Vera, Irene Zabala Gutierrez, Alejandro Casillas-Rubio, Mohammed Alqudwa Fattouh, Antonio Benayas, Riccardo Marin, Marta Maria Natile, Miguel Manso Silvan, Juan Rubio-Zuazo and 4 more

Open access · hybridAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Khouloud HamraouiDepartment of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain.
Vivian Andrea Torres-VeraDepartment of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain.
Irene Zabala GutierrezDepartment of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain.ORCID 0000-0003-2756-0211
Alejandro Casillas-RubioDepartment of Optics, Complutense University of Madrid, E-28037 Madrid, Spain.
Mohammed Alqudwa FattouhDepartment of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain.ORCID 0000-0002-2961-8352
Antonio BenayasNanobiology Group, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0001-8741-0894
Riccardo MarinNanobiology Group, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0003-3270-892X
Marta Maria NatileDipartimento di Scienze Chimiche, Università di Padova, 35131 Padova, Padua, Italy.ORCID 0000-0001-5591-2670
Miguel Manso SilvanDepartamento de Física Aplicada, Universidad Autónoma de Madrid, 28049 Madrid, Spain.ORCID 0000-0002-5063-1607
Juan Rubio-ZuazoSpanish CRG BM25-SpLine Beamline at the ESRF, 38043 Grenoble, France.
Daniel JaqueNanobiology Group, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, 28034 Madrid, Spain.ORCID 0000-0002-3225-0667
Sonia MelleDepartment of Optics, Complutense University of Madrid, E-28037 Madrid, Spain.ORCID 0000-0002-9802-6908
Oscar G CalderónDepartment of Optics, Complutense University of Madrid, E-28037 Madrid, Spain.
Jorge Rubio-RetamaDepartment of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain.ORCID 0000-0002-1785-5844
Universidad Complutense de Madrid · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESConsejo Superior de Investigaciones Científicas · ESUniversidad Autónoma de Madrid · ESUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare-earth doped nanoparticles (RENPs) are attracting increasing interest in materials science due to their optical, magnetic, and chemical properties. RENPs can emit and absorb radiation in the second biological window (NIR-II, 1000-1400 nm) making them ideal optical probes for photoluminescence (PL) in vivo imaging. Their narrow emission bands and long PL lifetimes enable autofluorescence-free multiplexed imaging. Furthermore, the strong temperature dependence of the PL properties of some of these RENPs makes remote thermal imaging possible. This is the case of neodymium and ytterbium co-doped NPs that have been used as thermal reporters for in vivo diagnosis of, for instance, inflammatory processes. However, the lack of knowledge about how the chemical composition and architecture of these NPs influence their thermal sensitivity impedes further optimization. To shed light on this, we have systematically studied their emission intensity, PL decay time curves, absolute PL quantum yield, and thermal sensitivity as a function of the core chemical composition and size, active-shell, and outer-inert-shell thicknesses. The results revealed the crucial contribution of each of these factors in optimizing the NP thermal sensitivity. An optimal active shell thickness of around 2 nm and an outer inert shell of 3.5 nm maximize the PL lifetime and the thermal response of the NPs due to the competition between the temperature-dependent back energy transfer, the surface quenching effects, and the confinement of active ions in a thin layer. These findings pave the way for a rational design of RENPs with optimal thermal sensitivity.

Indexed as

core@shell@shellNIR, Quantum yield, PL lifetime.photoluminescence emissionrare earth nanoparticlesthermometry

Identifiers

PMID37390496
PMCPMC10347429
OpenAlexW4382752810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.